vs
LIGAND PHARMACEUTICALS INC（LGND）与RBB Bancorp（RBB）财务数据对比。点击上方公司名可切换其他公司
LIGAND PHARMACEUTICALS INC的季度营收约是RBB Bancorp的1.8倍（$59.7M vs $32.3M），LIGAND PHARMACEUTICALS INC净利率更高（75.1% vs 31.5%，领先43.6%），LIGAND PHARMACEUTICALS INC同比增速更快（39.4% vs 12.6%），LIGAND PHARMACEUTICALS INC自由现金流更多（$45.9M vs $42.6M），过去两年LIGAND PHARMACEUTICALS INC的营收复合增速更高（38.8% vs 7.0%）
利根制药是美国的生物制药企业，专注于收购和开发可产生特许权使用费的资产。截至2024年，公司的资产组合涵盖约90款覆盖多个治疗领域的药品的特许权使用权，可从多发性骨髓瘤治疗药物凯洛斯、Evomela，肾病治疗药物Filspari，以及肺炎球菌疫苗Vaxneuvance等知名产品中获得相关收益。
RBB银行控股公司是总部位于美国的金融控股集团，旗下核心主体为皇家商业银行，主要服务亚裔社群、中小微企业、不动产投资者及零售客户，提供商业信贷、储蓄存款、财富管理等多元金融服务，业务覆盖美国沿海核心都会区。
LGND vs RBB — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $59.7M | $32.3M |
| 净利润 | $44.8M | $10.2M |
| 毛利率 | — | — |
| 营业利润率 | 23.2% | 39.5% |
| 净利率 | 75.1% | 31.5% |
| 营收同比 | 39.4% | 12.6% |
| 净利润同比 | 244.1% | 132.1% |
| 每股收益（稀释后） | $2.42 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $59.7M | $32.3M | ||
| Q3 25 | $115.5M | $32.6M | ||
| Q2 25 | $47.6M | $35.8M | ||
| Q1 25 | $45.3M | $28.5M | ||
| Q4 24 | $42.8M | $28.7M | ||
| Q3 24 | $51.8M | $30.3M | ||
| Q2 24 | $41.5M | $27.5M | ||
| Q1 24 | $31.0M | $28.2M |
| Q4 25 | $44.8M | $10.2M | ||
| Q3 25 | $117.3M | $10.1M | ||
| Q2 25 | $4.8M | $9.3M | ||
| Q1 25 | $-42.5M | $2.3M | ||
| Q4 24 | $-31.1M | $4.4M | ||
| Q3 24 | $-7.2M | $7.0M | ||
| Q2 24 | $-51.9M | $7.2M | ||
| Q1 24 | $86.1M | $8.0M |
| Q4 25 | 23.2% | 39.5% | ||
| Q3 25 | 47.6% | 40.7% | ||
| Q2 25 | 17.7% | 36.1% | ||
| Q1 25 | -79.9% | 11.2% | ||
| Q4 24 | -22.5% | 17.6% | ||
| Q3 24 | 6.1% | 31.6% | ||
| Q2 24 | -46.0% | 35.6% | ||
| Q1 24 | 9.6% | 39.9% |
| Q4 25 | 75.1% | 31.5% | ||
| Q3 25 | 101.6% | 31.2% | ||
| Q2 25 | 10.2% | 26.1% | ||
| Q1 25 | -93.6% | 8.0% | ||
| Q4 24 | -72.6% | 15.3% | ||
| Q3 24 | -13.8% | 23.1% | ||
| Q2 24 | -125.0% | 26.4% | ||
| Q1 24 | 278.1% | 28.4% |
| Q4 25 | $2.42 | $0.59 | ||
| Q3 25 | $5.68 | $0.59 | ||
| Q2 25 | $0.24 | $0.52 | ||
| Q1 25 | $-2.21 | $0.13 | ||
| Q4 24 | $-1.70 | $0.26 | ||
| Q3 24 | $-0.39 | $0.39 | ||
| Q2 24 | $-2.88 | $0.39 | ||
| Q1 24 | $4.75 | $0.43 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $733.5M | $212.3M |
| 总债务越低越好 | — | $119.9M |
| 股东权益账面价值 | $1.0B | $523.4M |
| 总资产 | $1.6B | $4.2B |
| 负债/权益比越低杠杆越低 | — | 0.23× |
8季度趋势，按日历期对齐
| Q4 25 | $733.5M | $212.3M | ||
| Q3 25 | $664.5M | $234.9M | ||
| Q2 25 | $245.0M | $191.9M | ||
| Q1 25 | $208.9M | $238.8M | ||
| Q4 24 | $256.2M | $257.7M | ||
| Q3 24 | $219.6M | $349.4M | ||
| Q2 24 | $226.9M | $252.8M | ||
| Q1 24 | $310.6M | — |
| Q4 25 | — | $119.9M | ||
| Q3 25 | — | $119.8M | ||
| Q2 25 | — | $119.7M | ||
| Q1 25 | — | $119.6M | ||
| Q4 24 | — | $119.5M | ||
| Q3 24 | — | $119.4M | ||
| Q2 24 | — | $119.3M | ||
| Q1 24 | — | $119.2M |
| Q4 25 | $1.0B | $523.4M | ||
| Q3 25 | $950.2M | $514.3M | ||
| Q2 25 | $828.5M | $517.7M | ||
| Q1 25 | $795.5M | $510.3M | ||
| Q4 24 | $830.4M | $507.9M | ||
| Q3 24 | $841.2M | $509.7M | ||
| Q2 24 | $775.2M | $511.3M | ||
| Q1 24 | $806.5M | $514.0M |
| Q4 25 | $1.6B | $4.2B | ||
| Q3 25 | $1.5B | $4.2B | ||
| Q2 25 | $948.6M | $4.1B | ||
| Q1 25 | $905.4M | $4.0B | ||
| Q4 24 | $941.8M | $4.0B | ||
| Q3 24 | $954.9M | $4.0B | ||
| Q2 24 | $866.4M | $3.9B | ||
| Q1 24 | $913.9M | $3.9B |
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 0.23× | ||
| Q1 25 | — | 0.23× | ||
| Q4 24 | — | 0.24× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.9M | $43.4M |
| 自由现金流经营现金流 - 资本支出 | $45.9M | $42.6M |
| 自由现金流率自由现金流/营收 | 76.9% | 131.8% |
| 资本支出强度资本支出/营收 | 0.0% | 2.5% |
| 现金转化率经营现金流/净利润 | 1.03× | 4.26× |
| 过去12个月自由现金流最近4个季度 | $48.9M | $73.5M |
8季度趋势，按日历期对齐
| Q4 25 | $45.9M | $43.4M | ||
| Q3 25 | $13.1M | $2.1M | ||
| Q2 25 | $15.8M | $21.7M | ||
| Q1 25 | $-25.4M | $7.8M | ||
| Q4 24 | $28.5M | $58.5M | ||
| Q3 24 | $36.5M | $24.5M | ||
| Q2 24 | $13.3M | $11.7M | ||
| Q1 24 | $18.7M | $4.8M |
| Q4 25 | $45.9M | $42.6M | ||
| Q3 25 | $13.1M | $1.8M | ||
| Q2 25 | $15.6M | $21.6M | ||
| Q1 25 | $-25.7M | $7.6M | ||
| Q4 24 | $27.8M | $57.7M | ||
| Q3 24 | $35.9M | $24.2M | ||
| Q2 24 | $12.9M | $11.5M | ||
| Q1 24 | $18.6M | $4.7M |
| Q4 25 | 76.9% | 131.8% | ||
| Q3 25 | 11.3% | 5.4% | ||
| Q2 25 | 32.7% | 60.2% | ||
| Q1 25 | -56.6% | 26.7% | ||
| Q4 24 | 64.8% | 201.0% | ||
| Q3 24 | 69.4% | 80.0% | ||
| Q2 24 | 31.1% | 42.0% | ||
| Q1 24 | 60.1% | 16.6% |
| Q4 25 | 0.0% | 2.5% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.4% | 0.3% | ||
| Q1 25 | 0.5% | 0.6% | ||
| Q4 24 | 1.7% | 2.7% | ||
| Q3 24 | 1.2% | 0.8% | ||
| Q2 24 | 1.0% | 0.5% | ||
| Q1 24 | 0.3% | 0.5% |
| Q4 25 | 1.03× | 4.26× | ||
| Q3 25 | 0.11× | 0.21× | ||
| Q2 25 | 3.26× | 2.32× | ||
| Q1 25 | — | 3.39× | ||
| Q4 24 | — | 13.34× | ||
| Q3 24 | — | 3.50× | ||
| Q2 24 | — | 1.61× | ||
| Q1 24 | 0.22× | 0.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LGND
| Intangible Royalty Assets | $40.7M | 68% |
| Financial Royalty Assets | $9.8M | 16% |
| Material Sales Captisol | $7.8M | 13% |
| Vaxneuvance | $1.4M | 2% |
RBB
暂无分部数据
